References

Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice

10.1093/humupd/dmt037 · 2014 · External reference

Poor responders in in vitro fertilization (IVF) therapy: the challenge continues

2011 · External reference

Cumulative live birth rates and number of oocytes retrieved in women of advanced age. A single centre analysis including 4500 women ≥38 years old

10.1093/humrep/dey295 · 2018 · External reference

Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos

10.1093/humrep/dev316 · 2016 · External reference

Association between the number of oocytes and cumulative live birth rate: A systematic review

10.1016/j.bpobgyn.2022.102307 · 2023 · External reference

Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including ∼15,000 women

10.1016/j.fertnstert.2018.04.039 · 2018 · External reference

ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria

10.1093/humrep/der092 · 2011 · External reference

A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept

10.1016/j.fertnstert.2016.02.005 · 2016 · External reference

Implementing the ESHRE 'poor responder' criteria in research studies: methodological implications

10.1093/humrep/deu135 · 2014 · External reference

Bologna vs. POSEIDON criteria as predictors of the likelihood of obtaining at least one euploid embryo in poor ovarian response: an analysis of 6,889 cycles

10.1016/j.fertnstert.2023.05.007 · 2023 · External reference

The POSEIDON stratification - moving from poor ovarian response to low prognosis

10.5935/1518-0557.20200100 · 2021 · External reference

First Bologna, then Poseidon: What are we still missing to personalize care for patients undergoing assisted reproductive technology with a poor prognosis

10.1016/j.fertnstert.2023.06.028 · 2023 · External reference

Diminished ovarian reserve, premature ovarian failure, poor ovarian responder--a plea for universal definitions

10.1007/s10815-015-0595-y · 2015 · External reference

Unresolved reference

External reference

Anti-mullerian hormone for the prediction of ovarian response in progestin-primed ovarian stimulation protocol for IVF

10.3389/fendo.2019.00325 · 2019 · External reference

ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025

10.1093/humrep/deag018 · 2026 · External reference

Editorial: Diminished ovarian reserve and poor ovarian response: diagnostic and therapeutic management

10.3389/fphys.2022.827678 · 2022 · External reference

Assessment indicators of ovarian response during controlled ovarian stimulation: influencing factors and clinical value

10.3389/fendo.2026.1793202 · 2026 · External reference

Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial

10.1016/j.fertnstert.2016.10.033 · 2017 · External reference

A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients

10.1093/humrep/deab155 · 2021 · External reference

Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial

10.1016/j.rbmo.2021.01.023 · 2021 · External reference

Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles

10.1016/j.rbmo.2018.12.032 · 2019 · External reference

Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Mullerian hormone and body weight

10.1016/j.rbmo.2021.08.024 · 2021 · External reference

A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol

10.1093/humrep/deac061 · 2022 · External reference

BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle

10.1093/humrep/deae092 · 2024 · External reference

Unresolved reference

External reference

Cumulative live birth rates in low-prognosis women

10.1093/humrep/dez051 · 2019 · External reference

Live birth rates in different subgroups of poor ovarian responders according to Bologna and POSEIDON group classification criteria

10.1016/j.jogoh.2021.102169 · 2021 · External reference

Live birth rates in Bologna poor responders treated with ovarian stimulation for IVF/ICSI

10.1016/j.rbmo.2013.11.010 · 2014 · External reference

Evaluation of the follitropin delta and clomiphene citrate combination in low prognosis women undergoing in vitro fertilization: A retrospective study

10.31083/ceog43781 · 2025 · External reference

A multicentric real-world observational study to describe the use and efficacy of follitropin delta for IVF/ICSI procedures in patients at risk of hypo-response

10.3389/frph.2025.1650946 · 2025 · External reference

Cumulative live birth rate after IVF: trend over time and the impact of blastocyst culture and vitrification

10.1093/hropen/hoab021 · 2021 · External reference

Cumulative live birth rate: time for a consensus

10.1093/humrep/dev263 · 2015 · External reference

Pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line

10.1002/jcph.328 · 2014 · External reference

Dose-exposure proportionality of a novel recombinant follicle-stimulating hormone (rFSH), FE 999049, derived from a human cell line, with comparison between Caucasian and Japanese women after subcutaneous administration

10.1007/s40261-015-0276-8 · 2015 · External reference

Pharmacokinetics and safety of follitropin delta in gonadotropin down-regulated healthy Chinese women

10.1007/s40261-022-01232-9 · 2023 · External reference